Literature DB >> 6203562

Elevation of substance P-like peptides in the CSF of psychiatric patients.

R Rimón, P Le Grevés, F Nyberg, L Heikkilä, L Salmela, L Terenius.   

Abstract

Using a radioimmunoassay procedure substance P-like activity was measured in samples of human CSF obtained from 12 patients with major depressive disorder, 12 with schizophrenia, and 15 control cases diagnosed as psychiatrically normal. Levels were significantly higher in CSF of patients with depressive disorder as compared with schizophrenic patients or controls. Chemical characterization revealed that the measured activity was less basic than substance P itself and might be due to C-terminal fragments. A component reacting with an antiserum highly specific for the substance P[1-7]fragment was found in CSF of patients with depressive disorder. The results indicate that substance P-related peptides may be biological markers in psychoses, particularly in major depressive disorder.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203562

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  16 in total

1.  Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain.

Authors:  Jarmo Hietala; Mikko J Nyman; Olli Eskola; Aki Laakso; Tove Grönroos; Vesa Oikonen; Jörgen Bergman; Merja Haaparanta; Sarita Forsback; Päivi Marjamäki; Pertti Lehikoinen; Michael Goldberg; Donald Burns; Terence Hamill; Wai-Si Eng; Alexandre Coimbra; Richard Hargreaves; Olof Solin
Journal:  Mol Imaging Biol       Date:  2005 Jul-Aug       Impact factor: 3.488

Review 2.  Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.

Authors:  Inga Herpfer; Klaus Lieb
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat.

Authors:  Liliane J Dableh; Kiran Yashpal; Joseph Rochford; James L Henry
Journal:  Eur J Pharmacol       Date:  2004-12-28       Impact factor: 4.432

4.  Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.

Authors:  Rebecca Fransson; Gunnar Nordvall; Johan Bylund; Anna Carlsson-Jonsson; Jadel M Kratz; Richard Svensson; Per Artursson; Mathias Hallberg; Anja Sandström
Journal:  ACS Med Chem Lett       Date:  2014-10-29       Impact factor: 4.345

Review 5.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10

Review 6.  Advances in the treatment of depression.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  NeuroRx       Date:  2006-01

7.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

8.  Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats.

Authors:  Karl Ebner; Nadia M Rupniak; Alois Saria; Nicolas Singewald
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

Review 9.  Depression and antidepressants: molecular and cellular aspects.

Authors:  Cristina Lanni; Stefano Govoni; Adele Lucchelli; Cinzia Boselli
Journal:  Cell Mol Life Sci       Date:  2009-06-12       Impact factor: 9.261

Review 10.  Idiopathic pain and depression.

Authors:  L von Knorring; L Ekselius
Journal:  Qual Life Res       Date:  1994-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.